Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Document Details

Document Type
Pub Defense Publication
Publication Date
Aug 17, 2016
Source ID
10.15252/emmm.201606540

Entities

People

  • Erik Portelius
  • Henrik Zetterberg
  • Kaj Blennow
  • Michael Weiner
  • Niklas Mattsson
  • Oskar Hansson
  • Philip S Insel
  • Sebastian Palmqvist
  • The Alzheimer’s Disease Neuroimaging Initiative*

Organizations

  • Alzheimer's Association
  • Alzheimer's Disease Neuroimaging Initiative
  • Alzheimer's Drug Discovery Foundation
  • BioClinica
  • Biogen
  • Bristol-Myers Squibb
  • Canadian Institutes of Health Research
  • Chiron Corporation
  • Eisai
  • Eli Lilly and Company
  • European Research Council
  • Foundation for the National Institutes of Health
  • GE HealthCare
  • Greta och Johan Kocks stiftelser
  • Hjärnfonden
  • Hoffmann-La Roche
  • Innogenetics
  • Johnson & Johnson
  • Johnson & Johnson Pharmaceutical Research and Development
  • Knut and Alice Wallenberg Foundation
  • Lund University
  • Magnus Bergvalls Stiftelse
  • Medpace
  • Merck & Co.
  • Meso Scale Diagnostics (United States)
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute on Aging
  • National Institutes of Health
  • Perrigo Company Plc
  • Pfizer
  • Roche (United States)
  • Sahlgrenska University Hospital
  • Skåne University Hospital
  • Swedish Research Council
  • Takeda Pharmaceutical Company
  • Torsten Söderberg Foundation
  • United States Department of Defense
  • University College London
  • University of California, San Francisco